SEC Form 4 · accession 0000899243-18-002883
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis M Lanfear
Officer — See Remarks · Director
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | holding | — | — | — | 92,619 | D | ||
| Common Stock, $0.0001 par valueF1 | holding | — | — | — | 1,337,566 | I | By Trust | |
| Common Stock, $0.0001 par valueF2 | holding | — | — | — | 86,965 | I | By LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $10.05 | Feb 1, 2018 | A | 400,000 | A | — | Feb 1, 2028 | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
- F2These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
- F3The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Remarks
President and Chief Executive Officer